Skip to content Skip to navigation


This lawsuit alleges that Constant Contact failed to disclose the true nature of its forecasted revenues insofar as its customer conversion rate was less than announced and that customers were opting for lower priced services.

shareholder of whole foods sues for securities fraud

This lawsuit alleges that Whole Foods misrepresented to shareholders that its operational controls were strong yet the company routinely overstated the weight of its pre-packaged products and overcharged customers. This caused Whole Foods' stock to be artificially inflated.

Part of Forterus, an AAC Facility

This lawsuit alleges that AAC Holdings and its CEO failed to disclose to investors that the company, the CEO, and other employees were under criminal investigation for murder in connection with the operation of its facilities.

TriNet Group Shareholder Litigation

This lawsuit alleges Trinet misrepresented to investors the accurate costs associated with workers compensation claims.  Specifically, that the company was experiencing greater than announced worker compensation costs even after analysts queried executives about the lower-than-industry average cost projections.

Abengoa  sued for securities fraud

This lawsuit alleges that since November 12, 2014, Abengoa has misrepresented the liquidity of  its balance sheet in corporate reports filed with the SEC and in conference calls with financial analysts. 

Resource Capital shareholder accuses company of stock fraud

This securities fraud class action alleges that Resource Capital should have disclosed its exposure to the Puerto Rican economy sooner than it did and therefore the REIT was trading at an artificially inflated value.

Plains All American Pipeline shareholder suit

This securities fraud class action alleges that Plains All American Pipeline issued false and misleading statements concerning its pipeline monitoring, maintenance and spill response measures, as well as its compliance with federal regulations governing its pipeline operations.

Tecfidera Capsules

This lawsuit alleges that, during the first half of 2015, Biogen purposefully overstated its future revenue growth, based largely on expectations for its flagship drug TECFIDERA, and that the overstated forecast artificially inflated the Biogen stock price.

Northwest Biotherapuetics shareholders sues for securities fraud

This securities class action alleges that executives at Northwest Biotherapeutics overstated or misstated results from ongoing clinical trials of certain therapies and engaged in an undisclosed stock promotion campaign to artificially inflate the company's stock price.

Super Micro Shareholder Lawsuit

This securities fraud class action alleges that Super Micro Computers materially misstated expenses for at least five fiscal quarters.  These misstatements could have a material effect on reported net income.  Super Micro Computers as a result could not issue its most recent financial statements.